{"filing":{"accession_number":"0001493152-26-033364","cik":"0001589150","ticker":"RGBPP","company_name":"Regen BioPharma Inc","form":"8-K","filing_date":"2026-07-15","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1589150/000149315226033364/form8-k.htm"},"events":[{"id":18151,"run_id":16305,"accession_number":"0001493152-26-033364","anchor_item_number":null,"event_type":"going_concern","event_domain":"terminal","is_material":true,"confidence":0.75,"summary":"The filing discloses in Item 4.01 that the prior auditor's (BCRG's) audit reports for fiscal years ended September 30, 2025 and 2024 \"included an explanatory paragraph indicating that there was substantial doubt as to the Company's ability to continue as a going concern.\" This is a material disclosure of going-concern uncertainty that would significantly affect a reasonable investor's assessment of the registrant's viability.","company_name":"Regen BioPharma Inc","ticker":"RGBPP","filing_date":"2026-07-15","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":16873,"accession_number":"0001493152-26-033364","item_number":null,"item_title":null,"event_type":"going_concern","event_domain":"terminal","is_material":true,"confidence":0.75,"reasoning":"The filing discloses in Item 4.01 that the prior auditor's (BCRG's) audit reports for fiscal years ended September 30, 2025 and 2024 \"included an explanatory paragraph indicating that there was substantial doubt as to the Company's ability to continue as a going concern.\" This is a material disclosure of going-concern uncertainty that would significantly affect a reasonable investor's assessment of the registrant's viability.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-15T20:19:38.997195+00:00","company_name":"Regen BioPharma Inc","ticker":"RGBPP","filing_date":"2026-07-15"}]}